WallStSmart

ResMed Inc (RMD)vsSociedad Quimica y Minera de Chile SA ADR B (SQM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 18% more annual revenue ($5.40B vs $4.58B). RMD leads profitability with a 27.5% profit margin vs 12.9%. SQM appears more attractively valued with a PEG of 0.46. RMD earns a higher WallStSmart Score of 70/100 (B).

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34

SQM

Strong Buy

66

out of 100

Grade: B-

Growth: 6.7Profit: 7.0Value: 9.3Quality: 7.3
Piotroski: 6/9Altman Z: 2.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued
SQMUndervalued (+22.0%)

Margin of Safety

+22.0%

Fair Value

$96.41

Current Price

$79.16

$17.25 discount

UndervaluedFair: $96.41Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

SQM4 strengths · Avg: 9.0/10
PEG RatioValuation
0.4610/10

Growing faster than its price suggests

EPS GrowthGrowth
52.3%10/10

Earnings expanding 52.3% YoY

Operating MarginProfitability
28.3%8/10

Strong operational efficiency at 28.3%

Revenue GrowthGrowth
23.3%8/10

Revenue surging 23.3% year-over-year

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

SQM1 concerns · Avg: 4.0/10
P/E RatioValuation
37.4x4/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bull Case : SQM

The strongest argument for SQM centers on PEG Ratio, EPS Growth, Operating Margin. Revenue growth of 23.3% demonstrates continued momentum. PEG of 0.46 suggests the stock is reasonably priced for its growth.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : SQM

The primary concerns for SQM are P/E Ratio.

Key Dynamics to Monitor

RMD profiles as a mature stock while SQM is a growth play — different risk/reward profiles.

SQM carries more volatility with a beta of 1.04 — expect wider price swings.

SQM is growing revenue faster at 23.3% — sustainability is the question.

SQM generates stronger free cash flow (317M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 66/100), backed by strong 27.5% margins and 11.0% revenue growth. SQM offers better value entry with a 22.0% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Sociedad Quimica y Minera de Chile SA ADR B

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Sociedad Qumica y Minera de Chile SA produces and distributes specialty plant nutrients, iodine and its derivatives, lithium and its derivatives, potassium chloride and sulfate, industrial chemicals and other products and services worldwide. The company is headquartered in Santiago, Chile.

Want to dig deeper into these stocks?